%0 Journal Article
%T Sarcopenia is a predictive marker for response to erlotinib in patients with lung adenocancer
%A Havva Cinkir
%A Tulay Kus
%A Gokmen Aktas
%A Umut Elboga
%J Clinical Cancer Investigation Journal
%@ 2278-0513
%D 2021
%V 10
%N 6
%R 10.4103/ccij.ccij_185_20
%P 294-299
%X 
Background: Adenocancer pathologic subtype, smoking history, and women gender have been known to predict the parameters such as the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer (NSCLC); however, we need new predictive markers as well as driver mutations for better treatment options. The aim of this study is to investigate the predictive role of sarcopenia in lung adenocancer patients treated with erlotinib. Materials and Methods: This study was designed as retrospectively. Skeletal muscle index (SMI) was measured with a single cross-sectional area of the muscle at the third lumber vertebra (L3, cm2)/(height × height)(m2). Sarcopenia was defined by median cutoff values of SMI of women (
%U https://ccij-online.org/article/sarcopenia-is-a-predictive-marker-for-response-to-erlotinib-in-patients-with-lung-adenocancer-933